Trial Profile
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of 14C-ALS-008176 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2017
Price :
$35
*
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Alios BioPharma
- 22 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2014 New trial record